Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients*

Abstract

In this phase II, randomized, controlled trial, high-dose N-acetylcysteine was no more effective than placebo in attenuating cardiopulmonary bypass-related acute renal failure in high-risk cardiac surgery patients.